During the last session, Gritstone bio Inc. (NASDAQ:GRTS)’s traded shares were 0.58 million, with the beta value of the company hitting 0.55. At the end of the trading day, the stock’s price was $2.68, reflecting an intraday gain of 2.29% or $0.06. The 52-week high for the GRTS share is $14.42, that puts it down -438.06 from that peak though still a striking 36.19% gain since the share price plummeted to a 52-week low of $1.71. The company’s market capitalization is $194.43M, and the average intraday trading volume over the past 10 days was 0.63 million shares, and the average trade volume was 1.21 million shares over the past three months.
Gritstone bio Inc. (GRTS) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 2.00. GRTS has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.4.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Gritstone bio Inc. (GRTS) registered a 2.29% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 2.29% in intraday trading to $2.68 this Friday, 07/15/22, hitting a weekly high. The stock’s 5-day price performance is -3.60%, and it has moved by 27.62% in 30 days. Based on these gigs, the overall price performance for the year is -64.83%. The short interest in Gritstone bio Inc. (NASDAQ:GRTS) is 2.81 million shares and it means that shorts have 1.84 day(s) to cover.
The consensus price target of analysts on Wall Street is $11.33, which implies an increase of 76.35% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2.00 and $20.00 respectively. As a result, GRTS is trading at a discount of -646.27% off the target high and 25.37% off the low.
Gritstone bio Inc. (GRTS) estimates and forecasts
Statistics show that Gritstone bio Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Gritstone bio Inc. (GRTS) shares have gone down -59.15% during the last six months, with a year-to-date growth rate less than the industry average at -60.00% against 1.20. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -21.20% this quarter and then drop -13.90% in the quarter after that. In the rating firms’ projections, revenue will decrease -65.10% compared to the previous financial year.
Revenue for the current quarter is expected to be $3.19 million as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to $3.21 million by the end of Sep 2022. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $2.84 million and $2.61 million respectively. In this case, analysts expect current quarter sales to grow by 12.20% and then jump by 22.80% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -7.50%. While earnings are projected to return 65.80% in 2022.
Gritstone bio Inc. is due to release its next quarterly earnings between August 03 and August 08. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Gritstone bio Inc. (NASDAQ:GRTS)’s Major holders
Gritstone bio Inc. insiders own 2.97% of total outstanding shares while institutional holders control 55.58%, with the float percentage being 57.28%. Redmile Group, LLC is the largest shareholder of the company, while 179 institutions own stock in it. As of Mar 30, 2022, the company held over 6.87 million shares (or 9.44% of all shares), a total value of $18.42 million in shares.
The next largest institutional holding, with 5.24 million shares, is of Frazier Life Sciences Management, L.P. ‘s that is approximately 7.19% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $14.04 million.
Also, the Mutual Funds coming in first place with the largest holdings of Gritstone bio Inc. (GRTS) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Mar 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 1.69 million shares. This amounts to just over 2.32 percent of the company’s overall shares, with a $4.54 million market value. The same data shows that the other fund manager holds slightly less at 0.91 million, or about 1.25% of the stock, which is worth about $2.45 million.